

# Newcastle University e-prints

---

**Date deposited:** 11<sup>th</sup> November 2011

**Version of file:** Published

**Peer Review Status:** Peer reviewed

## Citation for item:

Ponchel F, Toomes C, Bransfield K, Leong FT, Field SL, Douglas SH, Bell SM, Combaret V, Puisieux A, Mighell AJ, Robinson PA, Inglehearn CF, Isaacs JD, Markham AF. [Real-time PCR based on SYBR-green fluorescence: An alternative to the TaqMan assay for a relative quantification of gene rearrangements, gene amplifications and micro gene deletions.](#) *BMC Biotechnology* 2003, **3**, 18.

## Further information on publisher website:

<http://www.biomedcentral.com>

## Publisher's copyright statement:

© 2003 Ponchel et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

OR:

The definitive version of this article is published by [publisher name], [year] and is available at:

<http://dx.doi.org/10.1186/1472-6750-3-18>

Always use the definitive version when citing.

## Use Policy:

The full-text may be used and/or reproduced and given to third parties in any format or medium, without prior permission or charge, for personal research or study, educational, or not for profit purposes provided that:

- A full bibliographic reference is made to the original source
- A link is made to the metadata record in Newcastle E-prints
- The full text is not changed in any way.

The full-text must not be sold in any format or medium without the formal permission of the copyright holders.

**Robinson Library, University of Newcastle upon Tyne, Newcastle upon Tyne.  
NE1 7RU. Tel. 0191 222 6000**

Methodology article

Open Access

## Real-time PCR based on SYBR-Green I fluorescence: An alternative to the TaqMan assay for a relative quantification of gene rearrangements, gene amplifications and micro gene deletions

Frederique Ponchel\*<sup>1</sup>, Carmel Toomes<sup>1</sup>, Kieran Bransfield<sup>1</sup>, Fong T Leong<sup>1</sup>, Susan H Douglas<sup>1</sup>, Sarah L Field<sup>1</sup>, Sandra M Bell<sup>1</sup>, Valerie Combaret<sup>2</sup>, Alain Puisieux<sup>2</sup>, Alan J Mighell<sup>1</sup>, Philip A Robinson<sup>1</sup>, Chris F Inglehearn<sup>1</sup>, John D Isaacs<sup>1</sup> and Alex F Markham<sup>1</sup>

Address: <sup>1</sup>Molecular Medicine Unit, University of Leeds, Leeds, UK and <sup>2</sup>Centre Anti-cancer Leon Berard, Lyon, France

Email: Frederique Ponchel\* - mmefp@leeds.ac.uk; Carmel Toomes - c.toomes@leeds.ac.uk; Kieran Bransfield - kieran.bransfield@leedsth.nhs.uk; Fong T Leong - medftl@leeds.ac.uk; Susan H Douglas - medshdo@leeds.ac.uk; Sarah L Field - medslf@leeds.ac.uk; Sandra M Bell - medsmb@leeds.ac.uk; Valerie Combaret - COMBARET@lyon.fnclcc.fr; Alain Puisieux - puisieux@lyon.fnclcc.fr; Alan J Mighell - desajm@south-01.novell.leeds.ac.uk; Philip A Robinson - des6par@leeds.ac.uk; Chris F Inglehearn - cinglehe@hgmp.mrc.ac.uk; John D Isaacs - rrrjdi@leeds.ac.uk; Alex F Markham - msj6afm@stjames.leeds.ac.uk

\* Corresponding author

Published: 13 October 2003

BMC Biotechnology 2003, 3:18

This article is available from: <http://www.biomedcentral.com/1472-6750/3/18>

Received: 16 April 2003

Accepted: 13 October 2003

© 2003 Ponchel et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

### Abstract

**Background:** Real-time PCR is increasingly being adopted for RNA quantification and genetic analysis. At present the most popular real-time PCR assay is based on the hybridisation of a dual-labelled probe to the PCR product, and the development of a signal by loss of fluorescence quenching as PCR degrades the probe. Though this so-called 'TaqMan' approach has proved easy to optimise in practice, the dual-labelled probes are relatively expensive.

**Results:** We have designed a new assay based on SYBR-Green I binding that is quick, reliable, easily optimised and compares well with the published assay. Here we demonstrate its general applicability by measuring copy number in three different genetic contexts; the quantification of a gene rearrangement (T-cell receptor excision circles (TREC) in peripheral blood mononuclear cells); the detection and quantification of *GLI*, *MYC-C* and *MYC-N* gene amplification in cell lines and cancer biopsies; and detection of deletions in the *OPA1* gene in dominant optic atrophy.

**Conclusion:** Our assay has important clinical applications, providing accurate diagnostic results in less time, from less biopsy material and at less cost than assays currently employed such as FISH or Southern blotting.


### Background

The detection and quantification of gene rearrangement, amplification, translocation or deletion is a significant

problem, both in research and in a clinical diagnostic setting. Real-time PCR has become a well-established procedure for quantifying levels of gene expression [1–3]. Its

power resides in the ability to detect, at every cycle of the PCR, the amount of PCR product (amplicon) using fluorescence. Several approaches have been employed to detect PCR products. The most popular, the 5'-nuclease assay, is based on the specific hybridisation of a dual-labelled TaqMan [4] probe to the PCR product. Another approach is based upon the binding of the fluorescent dye SYBR-Green I into the PCR product (PE Applied Biosystems, Warrington, UK). Although both assays are potentially rapid and sensitive, their principles of detection and optimisation are different, as is the resulting price per assay. Here we report the development and rigorous testing of a real-time PCR assay using the inexpensive SYBR-Green I technology.

We developed our assay initially for the detection of a gene rearrangement in the T-cell receptor locus. The immune system requires a large diversity of immunoglobulins (Ig) and T-cell receptors (TCR) to screen the body for pathogens. Such diversity is achieved by rearranging pre-existing segments of the TCR or IG genes randomly [5]. This process involves the excision of intervening segments of DNA, the ends of which are subsequently ligated to form T-cell receptor excision small circles of episomal DNA (TRECs – Figure 1). The level of TRECs in peripheral blood mononuclear cells provides a surrogate measure of thymic activity and as such, there is a need for a rapid, cheap and reliable assay to quantify TRECs in clinical situations where the immune system may be compromised.



**Figure 1**

**Formation of TRECs.** During their passage through the thymus, T-cell precursors rearrange their T-cell receptor (TCR) genes. This step requires the excision of segments of DNA, the ends of which are subsequently ligated to form small circles of episomal DNA (signal and coding), hereafter referred to as T-cell receptor excision circles (TRECs). The sequences remaining after recombination provides the target for a PCR detection of TREC. Each mature T-cell exiting the thymus and released into the circulation, therefore contains episomal TRECs. As these cells replicate in the peripheral blood, TRECs are not replicated but are distributed among daughter cells and are gradually diluted in the peripheral T-cell pool. Therefore, by measuring the proportion of peripheral T-cells containing TRECs, an estimate of recent thymic function can be obtained.

We have also gone on to demonstrate the more general applicability of our assay by using it to quantify other genetic events. Firstly we assayed gene amplification in cancer. The glioma-associated oncogene *GLI* was identified in 1987 and found amplified in double minutes in glioblastoma [6]. It was mapped by *in situ* hybridisation to 12q13-14 [7] a chromosomal region demonstrating amplification in subsets of glioblastomas and sarcomas [8,9]. We used our assay to quantify *GLI* amplification in five tumor-derived cell lines. Similarly the *MYC* oncogene is amplified in a number of pathologies, particularly in neuroblastoma where *MYC-N* amplification is a diagnostic marker [10]. We quantified *MYC-C* amplification in cell lines and *MYC-N* amplification in a set of tumour samples where it was associated with a diagnostic and prognosis of neuroblastoma [10].

Lastly we assayed genomic copy number as a test for gene deletion in a dominant Mendelian disorder. Autosomal dominant optic atrophy (ADOA) is the most common hereditary optic neuropathy, resulting in progressive loss of visual fields, colour vision defects and in many cases registered blindness. The most common cause of ADOA is mutations in the *OPA1* gene on chromosome 3q28-q29. Many different mutations have been described in families with ADOA, including point mutations, small deletions and insertions [11] and the deletion of either the entire gene [12] or of exon 20 alone [13]. We applied our assay to the detection of a micro-deletion of the *OPA1* gene in a family with ADOA where such a deletion had previously been identified.

## Results and Discussion

### The principle of Real-time PCR quantification


A real-time-PCR read-out is given as the number of PCR cycles ("cycle threshold" Ct) necessary to achieve a given level of fluorescence. For this study, the Ct was fixed in the exponential phase of the PCR (Figure 2A, linear part of the fluorescence curve). During the initial PCR cycles, the fluorescence signal emitted by SYBR-Green I bound to PCR product was usually too weak to register above background. Indeed, a difference could not be defined until after about 15 PCR cycles. During the exponential phase of the PCR the fluorescence doubled at each cycle. After 35 cycles, the intensity of fluorescent signal usually began to plateau, indicating that the PCR had reached a saturation status. As a Ct is proportional to the logarithm of initial amount of target in a sample, the relative concentration of one target with respect to another is reflected in the difference in cycle number ( $\Delta Ct$ ) necessary to achieve the same level of fluorescence (Figure 2A).

### Optimisation of Real-time PCR conditions

Optimal design of the PCR primers is essential for accurate and specific quantification using real-time PCR. For

the assay described herein, detection is based on the binding of the SYBR-Green I dye into double stranded PCR products, which is a sequence independent process. While this assay is cheaper than the more commonly used 5' nuclease assay, it loses the additional level of specificity introduced by the hybridisation of the PCR product to a specific fluorescent TaqMan probe. The sensitivity of detection with SYBR-Green I may therefore be compromised by the formation of primer-dimers, lack of specificity of the primers, primer concentration (which can be limiting) and the formation of secondary structures in the PCR product. All of these factors could lead to the creation of unexpected double-stranded DNA product, which would incorporate SYBR-Green I and register a fluorescent signal. The 5'-nuclease assay using TaqMan probes would also be compromised by primer dimers. Although they are not detected, they do alter the amplification efficiency of the specific product.

The optimisation of the primer concentration is essential. Each set of primers work best under different concentration conditions. Primer design is also very restrictive: the annealing temperature is restricted to 58–60°C, which corresponds to the optimal working conditions for the AmpliTaq Gold DNA polymerase enzyme (Perkin Elmer), and the length of the PCR product is set between 80 and 150 bp. The use of software dedicated to RT-PCR primer design, such as Primer Express™ (Perkin Elmer), is highly recommended. For all experiments described in this report, each pair of primers was designed following the manufacturer's instructions to amplify products from the genes of interest ranging from 81 to 122 bp (Primer Express™, Perkin Elmer). Primer concentration is usually determined to be optimal when specific amplification relative to primer-dimers was maximal in a positive versus negative control experiment. However, the choice of the most appropriate conditions for our assay corresponds to the combination of primer concentration allowing a ratio of target gene to reference gene of 1 in a DNA sample with no genetic abnormality. This ratio is calculated using the  $\Delta Ct$  methods ( $\Delta Ct = Ct \text{ of the target} - Ct \text{ of the reference}$ ). A delta Ct of 0 indicates a ratio of 1 between the target and the reference ( $2^{-\Delta Ct} = 2^0 = 1$ ). A number of factors can influence this assay, and the optimisation consists in compensating these factors to obtain a ratio of 1 in a DNA sample with no genetic abnormality. The inclusion of such a normal DNA sample on each experiment also provides a reference sample for a  $\Delta\Delta Ct$  method of calculation, however, as the normalisation will relate to a value close to 0 for the second  $\Delta Ct$ , both methods essentially give the same result.



**Figure 2**

**Real-time Optimisation. A) Real-time amplification plot.** Three real-time amplification plots are shown for *GAPDH* as target 2, *GLI* as target 1 and no-template controls (background at the bottom of the graph). DNA from the SJSAL cell line was used for this experiment. The cycle numbers (cycle threshold, Ct) necessary to achieve the given level of fluorescence of 2 (horizontal line), which lies in the log-linear phase of both PCR reactions, were 27.03 and 32.25 for target 1 and 2 respectively (vertical lines). A difference of  $32.65 - 27.03 = 5.62$  cycles between the two Ct, means that there was  $2^{5.62} = 49.2$  more of target 1 relative to target 2. This confirms an amplification of the *GLI* gene in this cell line. **B) and C). Dissociation curves for *GAPDH* (B) and signal *TREC* (C) PCR reactions.** Dissociation curves provide a graphical representation of the PCR product after the amplification process. A single peak in positive samples (graph +) suggests a single size product (*GAPDH* amplification from PBMC DNA). An absence of peak in the negative control sample (graph -) indicates the lack of primer dimer. Occasionally, primer-dimers were observed in negative control wells, (as shown by the arrow on plot C for signal *TREC* amplification from PBMC DNA). The melting temperature of each PCR product varies and is dependent on its sequence and size. A melting temperature of 81°C was observed for the *GAPDH* product (84 bp), which contained 17 Gs, 29 Cs, 17 As and 21 Ts. The signal *TREC* product (122 bp) had a melting temperature of 87°C and contained 19 Gs, 25 Cs, 33 As and 45 Ts. The occasional primer-dimers (indicated by the arrow on graph C) have a much lower melting temperature. **D) Primer concentration optimization.** Three sets of primers were designed to amplify 3 target genes (*OPAI*, *MYC-C* and *GLI*). A primer concentration optimization experiment was performed where all PCR conditions were the same apart from the primer concentration. The same PBMC DNA sample was used in all tests. Normalization was performed against *GAPDH* in this DNA sample using the delta Ct method. The primer concentration used for *GAPDH* in this assay was 100 nM. *MYC-C* (black bars) is optimally amplified at the concentrations of 500 nM for both primers with a ratio of 0.99. *GLI* (grey bars) is similarly detected over concentrations ranging from 100 to 500 nM for both primers however, with an optimal ratio of 0.98 at 300 nM. *OPAI* (open bars) is only detected at a primer concentration of 500 nM with a ratio of 0.95. Of note, excess of primer is detrimental to all 3 PCR assay as amplifications yielded less product for the 3 different targets at concentrations of 1000 nM for each primer.

**Table 1: Real-time nucleotide primer sequences**

| GENE          | FORWARD PRIMER                     | REVERSE PRIMER                      | ACCESSION NUMBER | PRODUCT LENGTH | PRIMER CONCENTRATION * |             | PCR EFFICIENCY * |             |
|---------------|------------------------------------|-------------------------------------|------------------|----------------|------------------------|-------------|------------------|-------------|
|               |                                    |                                     |                  |                | REFERENCE GENE         | TARGET GENE | REFERENCE GENE   | TARGET GENE |
| <i>hGAPDH</i> | AAC AGC GAC ACC CAT CCT C;         | CAT ACC AGG AAA TGA GCT TGA CAA     | NM_002046        | 81             |                        |             |                  |             |
| CODING        | CAC CTC TGG GCT ACG TGC TAG        | GAA CAC ATG CTG AGG TTT AAA GAG AAT | NG_001332        | 98             | 50/50                  | 300/300     | -2.87            | -2.84       |
| SIGNAL        | CAG AGG GGT GCC TCT GTC A          | GGA CCC CTC ACA AAG TGT CG          | NG_001332        | 142            | 100/100                | 100/100     | -2.87            | -2.93       |
| C-MYC         | TTC TAA GAG AAA TGT CCT GAG CAA TC | TCA AGA CTC AGC CAA GGT TGT G       | X00364           | 88             | 100/100                | 500/500     | -3.18            | -3.22       |
| GLI           | CCC AAT CAC AAG TCA GGT TCC T      | CCT ATG TGA AGC CCT ATT TGC C       | NM_005269        | 93             | 100/100                | 300/300     | -3.18            | -3.19       |
| N-MYC         | CTT TCA AAT CCG TCC CCT GTC        | AGA GGT TCC AGG GTC GTC TT          | Y00664           | 82             | 50/50                  | 300/300     | -3.29            | -3.30       |
| OPA1          | TGT GAT TGA AAA CAT CTA CCT TCC A  | TTT AAG CTT GAT ATC CAC TGT GGT GT  | NM_015560        | 82             | 50/50                  | 500/500     | -3.34            | -3.38       |
| MGAPDH        | GTC TCC TGC GAC TTC AGC            | TCA TTG TCA TAC CAG GAA ATG AGC     | NM_008084        | 107            |                        |             |                  |             |
| HOP           | TGG AGT ACA ACT TCA ACA AGG TCA A  | GGA CTC ACC TGC GTC TGC TC.         | AF492703         | 103            | 50/50                  | 300/300     | -3.2             | -3.18       |
| FLAG/HOP      | ATG GAC TAC AAG GAC GAT GAC CGA    | TGT TGA CCT TGT TGA AGT TGT ACT CC  | AF492703         | 107            | 50/50                  | 100/100     | -3.2             | -3.21       |


\* Concentrations used in individual assay for F/R primers (nM). \* PCR efficiency defined as the slope of the Log-linear phase of a dilution set as described in Figure 3A

Complete absence of primer dimer was rarely achieved in a PCR negative control (Figure 2B and 2C), however, in an experimental negative including a template but no target, dimers were not observed. Furthermore, the inclusion of a heat dissociation experiment at the end of the PCR suggests that a single product is present (even if an electrophoresis is used once at the end of the first optimisation plate to confirm it). The degree of an eventual primer-dimer contribution (Figure 2C) to the overall fluorescent signal of the PCR negative control can also be detected in such a dissociation experiment. As an example, 3 sets of primers were used to amplify 3 targets (*OPA1*, *GLI* and *MYC-C*) in an optimisation assay where the only variable was the concentration of primers in the reaction (Figure 2D). For these examples, the concentration of primer for *GAPDH* was 100 nM for *GLI* and *MYC-C* and 50 nM for *OPA1*. However, for other target genes it was necessary to either increase or decrease the primer concentration for *GAPDH* (see Table 1). For this demonstration, we used normal PBMC derived DNA template and normalised the expression of these 3 target genes to *GAPDH*. The optimisation experiment consists in finding the conditions necessary to obtain a ratio of for target gene to reference. The first set of primers (black bars, *MYC-C*) showed a bell shaped optimisation pattern where the intermediate concentrations were optimum and giving ratio of target to reference close to 1. The second set of primers (grey bars, *OPA1*) showed a plateau type of curve where most of the higher concentrations were of similar efficiency. The last primer set (open bars, *GLI*) showed poor amplification at both extremes of the concentration range, and a single, efficient concentration of primer. In these optimisation experiments, primer dimers were not observed. Higher primer concentration had a limiting effect on the PCR reaction and would be detrimental to the accuracy of the quantification.

For an accurate quantification it is also necessary to verify that PCR efficiency is independent of the initial amount of target DNA. Each pair of primers was therefore tested across several logs dilution series of a positive control DNA sample. Figure 3A shows such an experiment for TREC quantification (coding and signal). It was necessary to use cloned template for this purpose, as a TREC rearrangement sequence is not available in genomic DNA. The two plots obtained for the signal and coding TREC (and the internal reference gene, *GAPDH*), were linear, demonstrating equal efficiency of the individual PCR assays over a large range of initial template concentrations. The titration plots were also super-imposed, demonstrating that the three PCR assays were equally efficient despite the differences in PCR product sizes and base pair constitution. Similar experiments were performed for all the other genes, using genomic DNA however (data not shown, and Table 1).

#### DNA quantification

One of our major aims was to determine the limit of sensitivity of our assay in allowing accurate quantification of gene amplification, deletion or rearrangement from DNA extracted from relatively few cells. For this purpose we estimated the number of cells present in a given sample by real-time PCR quantification of the copy number of the housekeeping gene *GAPDH*, each cell having two allelic copies of this gene. In principle, any gene would be suitable, however, as we were expecting to look at deletions, amplifications and rearrangements, we chose a gene that was unlikely to be involved in any of these processes. We have assayed the linearity of the relationship between real-time Ct for *GAPDH* reading with cloned *GAPDH* target. The use of cloned template also provided a read-out that reflected the number of molecules present in the reaction, which could then be used for an absolute quantification (see Figure 4A). Therefore, Figure 3A also shows



**Figure 3**

**DNA quantification using the SYBR-Green I assay. A). The sensitivity of the GAPDH, signal and coding TREC PCR assays are similar.** Titration curves were obtained by taking cloned *GAPDH*, signal and coding TREC templates of known concentration and using these to create a seven log dilution series for each assay. The linearity of the plots shows the equal amplification of the assay over a range of input DNA concentrations. The superimposition of the plots proved that each assay was equally efficient despite the relative difference in product size (84, 98 and 122 bp), and allowed a comparison between genes. The coefficient of correlation for *GAPDH* (triangles) was  $R = -0.997$ ; for signal TREC (squares) was  $R = -0.980$  and for coding TREC (diamonds) was  $R = -0.995$ . **B). GAPDH real-time readout is a reliable measure of the DNA concentration of a sample.** Forty DNA samples were obtained independently from PBMCs, and their concentration was determined by measuring their OD at 260 nm (two readings were made for each sample at four different dilutions  $n = 8$ , reading at 280 nm were taken and ratio of OD 260/OD 280 were all  $> 1.8$ ). A SYBR-Green I real-time quantification of *GAPDH* was then performed, giving a second independent estimate of DNA concentration. We observed a significant correlation ( $R = -0.842$ ,  $P < 0.001$ ) between the concentrations estimated by real-time Ct and by OD measurement in each sample.

a standard curve correlating the *GAPDH*-Ct reading to the number of cloned *GAPDH* molecules, allowing us to correlate the *GAPDH*-Ct of a sample with a number of *GAPDH* molecules. This number, when divided by 2, would thereby correspond to the number of cells from which the DNA was initially extracted. We assayed the relationship between the amount of DNA in cell extracts and *GAPDH* readings. The relationship between *GAPDH*-

Cts and the spectrophotometer-measured concentrations of forty genomic DNA samples extracted from PBMCs under the same conditions but at different times and by different research workers is linear as demonstrated in Figure 3B. The relationship between the initial number of cells in a sample and the DNA concentration of the same sample was also linear (data not shown), indicating a similar efficiency of the DNA extraction method without

regard for the initial number of cells in the samples. Together these results validate the use of *GAPDH*-Cts as an internal measure of the amount of DNA in each sample, reflecting the number of cells present in that sample.

#### **Validation of the TRECs quantification assay**

The original PCR conditions described in the reports by Doueck and colleagues [14] were reproduced to clone two PCR products (380 bp each) for both signal and coding TRECs. Real-time PCR primers were designed flanking the site of the recombination, to amplify PCR products of 99 and 122 bp, specific for signal and coding TRECs respectively (see Figure 1). Optimisation and standardisation were performed (see Figure 2 and 3). Two quantification methods were used to compare a set of DNA samples extracted from CD4+T-cells in ten healthy individuals. The first method determined the number of TREC molecules per  $\mu\text{g}$  of DNA, relying on DNA concentration obtained by optical density readings. Our results were in line with published values [14,15] for a similar age group (Figure 4A). The second method estimated the number of cells in the reaction by quantifying *GAPDH* copy number as described above, giving the number of cells containing a TREC as a percentage of total cells (Figure 4A). Results obtained with these methods were comparable and could be super-imposed. The second method has the advantage of providing a more understandable scale. This method was validated on a sorted cell population of less than fifty cells (data not shown), demonstrating that it could be adapted to samples with a very small yield of DNA [16]. The reproducibility of the PCR assay was determined by including a standardisation sample in 17 consecutive PCR plates, run by 2 independent manipulators (Figure 4C). In this particular sample, the mean TREC content was 9.08 %, with a standard deviation of 0.611 %.

#### **Validation for an assay detecting gene amplification**

We next assessed the general applicability of our experimental procedure to determine levels of relative gene amplification. We used our assay to quantify *GLI* copy number in genomic DNA extracted from cell lines known to exhibit *GLI* gene amplification at various levels [17]. We proceeded through optimisation as in Figure 2. Analysis using our assay indicated slightly higher levels of amplification (black bars) than previously reported (open bars) [18] (Figure 5A). Similar results were observed when multiplex-fluorescent PCR was used to analyse *GLI* copy number in the DNA extracted from these cell lines (grey bars). We also looked for evidence of *MYC*-C gene amplification in two cell lines HT29 and colo320 [19] and in normal PBMCs using our assay. After performing optimisation, results (black bars) were similar to published amplification levels (open bars) for both cell lines but were normal in healthy PBMCs (Figure 5A).

We also applied the SYBR-Green I assay to tumour samples for the detection of the *MYC*-N gene amplification. These samples had been tested previously by standard procedures for the diagnosis of neuroblastoma using fluorescence *in-situ* hybridisation (FISH) [10]. Our results (Figure 5B, black bars) compared well with the established amplification factor recorded for these tumours (open bars) and confirmed the presence of *MYC*-N amplification in 6 tumours. Using the  $\Delta\Delta\text{Ct}$  methods of calculation with one of the sample becoming the reference (either sample 4777, 100 fold amplification or sample 4334, 50 fold amplification) does not change the results significantly.


#### **Validation for an assay detecting gene deletion in genomic DNA**

Point mutations and small insertions or deletions in the *OPA1* gene have been shown to underlie more than half of all cases of dominant optic atrophy. In addition two larger deletions in *OPA1* have been detected, each in a single family. One of these deletes exon 20 and the surrounding intronic DNA [13], while the other deletes the entire gene and over half a megabase of surrounding DNA [12]. Traditional PCR-based mutation detection methods such as single strand contamination polymorphism (SSCP) analysis would miss these mutations since only the normal allele would amplify. We therefore designed a SYBR-Green I assay to quantify the number of copies of *OPA1* exon 20 present in any given sample, which should therefore detect both of these deletions. We tested this on genomic DNA from patients and healthy members of the family (Figure 6A) with the deletion of the entire gene, and were able to confirm a reduction in relative copy number in these samples as compared to healthy members of the family (figure 6B and 6C). In this particular assay, exon 20 of the *OPA1* gene is the target sequence. It is 165 bp long and limited the design of exon specific primers. The ratio of target gene to reference obtained in normal PBMCs during optimisation was 0.96 (Figure 2C and Table 1). However, the  $\Delta\text{Ct}$ s in affected individual was on average more than 1 cycle compared to unaffected individuals indicating a reduction of at least 50%. We also applied this assay to the quantification of gene copy number in a transgenic mouse model. The gene *Hop* was 5' FLAG-tagged. Endogenous *Hop* sequences were also used as reference gene for the quantification. We identified founders carrying either 1 or 2 copies of the transgene (data not shown).

#### **Discussion**


There are major advantages of using real-time PCR compared to conventional semi-quantitative PCR. Firstly, the progression of the PCR reaction may be monitored after each cycle rather than at the end, thereby providing a much better quantification assay; secondly, very little






**Figure 4**

**Absolute and relative quantifications of TREC determined using the SYBR-Green I assay are equivalent.** We performed a quantification of TRECs by two methods. **(A)** Samples were quantified against a standard curve run in parallel with the samples, to obtain an absolute quantity of TRECs per µg of DNA. The results are described by the equation  $y = 96911 \exp(-0.0562x)$  where  $x$  represents age (years) and  $y$  TRECs per µg of DNA (extracted from CD4+T-cells) using an exponential regression model **(B)** A *GAPDH* and a TREC assay were run in parallel to normalize the number of TRECs to the number of CD4+T-cells in the sample. Linearity is described by the equation  $y = 69.013 \exp(-0.0432x)$  where  $x$  represents age (years) and  $y$  the proportion of cells containing a TREC. Both methods produced equivalent results as shown by the similarity in their equation parameters. **C.** The reproducibility of the second assay was tested using one sample, analyzed 17 times on consecutive PCR plates. There was 4.1% variability between the 17 measurements.



**Figure 5**

**Quantification of gene amplification by a SYBR-Green I assay. A) Gene amplification detected in cell lines.** Cell lines with known levels of gene amplification (open bars) were tested for *GLI* [17] or *MYC-C* [19] gene amplification using real-time PCR and/or QM-Multiplex PCR. Results obtained using the SYBR-Green I real-time assay (black bars, triplicates) correlated well with the levels of amplification for both genes described previously in these cell-lines. However, QM-Multiplex PCR gave lower levels of amplification in two out of five samples compared to reported results. **B) Detection of gene amplification in DNA extracted from neuroblastoma tumor samples.** Tumor samples with known levels of *MYC-N* gene amplification, established using standard FISH techniques (open bars, estimated 1, 10, 50 or 100 amplification fold) were tested for *MYC-N* gene amplification using our real-time PCR assay (black bars, triplicate). Results obtained correlated well with reported levels and confirmed either the presence of an *MYC-N* gene amplification in 6 out of 9 tumors or its absence in 3 tumors.



**Figure 6**

**Quantification of gene deletion by a SYBR-Green I assay. A. Pedigree of an ADOA family with a deletion of the entire *OPA1* gene.** Carriers of the deletion are indicated with filled symbols and normal individuals with open symbols [12]. **B. Real-time plot obtained for the quantification of the *OPA1* gene deletion.** Genomic DNA from 2 individuals (a carrier and a normal) was assayed for copy number of the *OPA1* gene using the SYBR-Green I real-time PCR assay. Real-time *OPA1* amplification plots for carriers (right panel) are consistently at least one cycle behind the plots obtained with *GAPDH*, while plots for *GAPDH* and *OPA1* in non-carriers are almost superimposed (left panel). **C. Quantification of the *OPA1* gene deletion in 13 members of the family.** DNA was extracted from family members indicated by letters on A. The *OPA1* versus *GAPDH* PCR assay was performed. Non-carriers showed a ratio close to 1 for the *GAPDH* versus *OPA1* quantification. In contrast, all carriers of the deletion showed a clear reduction in this ratio.

DNA is needed; thirdly it is a non-radioactive assay; and finally it can be performed in approximately two hours. The advantages of using SYBR-Green I quantification over a 5'-nuclease assay with TaqMan probes are the relative simplicity and the reduced cost of SYBR-Green I compared to TaqMan probes. The assay we have designed provides an accurate relative quantification of gene rearrangement, gene deletion and gene amplification. The principle used in this assay can be adapted to a large number of biological systems and could therefore have a significant impact on patient care by providing accurate results in a shorter time. Another major advantage of our assay is that it can be carried out with only a few biopsy cells. Archived material such as paraffin embedded tissue sections can be used. DNA can be extracted from such material using the same methodology (with no need for de-waxing) and used in a SYBR-Green I real-time assay (data not shown). Therefore our assay has significant advantages over other methods.

A real-time 5'-nuclease assay using TaqMan probes has recently been described for the detection of TRECs [20]. However, this relies on an absolute quantification of TRECs by normalisation to a standard curve using cloned template. In our hands, a number of practical problems were encountered with this approach. These included the potential risk of cross-contamination of equipment with the cloned template, the cost of repeating the standardisation but most importantly difficulties with quantification of DNA in small samples. This latter problem is particularly pertinent for following thymic function in biological samples in which T-cells are depleted. Our strategy allowed us to quantify TRECs in samples of less than one hundred cells. The lowest number of cells from which we were able to extract DNA and satisfactorily quantify TREC was 70 cells (data not shown) [16]. TREC measurements provide information about immune reconstitution in a number of clinical situations, including anti-HIV-therapy, chemotherapy and bone marrow or stem cell transplantation in cancer patients, and in autoimmune disease patients [14,16,21,22]. Despite recent reports describing the lack of a relationship between recent thymic activity and TREC measurement in non-T-cell depleted host, with controlled homeostasis [16,23], TREC are still the best means of assessing thymic output in situation where there are a limited number of T-cells to start with, such as following lymphodepletion achieved through therapeutical means [chemotherapy, [24]] or caused by disease activity (graft-versus-host disease [25] or viruses (HIV [20])).

Other gene rearrangements or translocations have been studied using real-time PCR. For example, the major and minor break-points of the chromosome 14 to 18 translocation t(14:18)(q32;q21) have been analysed in non-Hodgkins lymphomas using a 5'-nuclease assay with TaqMan probes [26] and results compared well with conven-

tional PCR (99 % concordance [27]). This TaqMan type of assay could easily be replaced by a SYBR-Green I assay as this simply reflects a change in the means of detection of the PCR product.

Compared to Southern blotting or FISH when used for the detection of gene amplification, our SYBR-Green I real-time PCR assay provides a rapid and accurate alternative. Furthermore, a FISH-based assay would require live material, which may not be available or easy to obtain, whereas the assay described here could be applied to tumour derived DNA, which is much more readily available. The use of the SYBR-Green I assay for the detection of gene amplification could have an important impact for patients as results are produced rapidly (in less than one day) with a minimal amount of biopsy material. The diagnosis and treatment of a number of severe conditions could benefit from the development of an assay based on our findings. For example, the multi-drug resistance phenotype in tumours results from the amplification of the *MDR* gene, which could be assayed quickly and cheaply as described above [28]. Similarly, an assay could be developed to identify *cyclin D1* and *MDM2* gene amplification. The former is a prognostic marker in breast carcinoma [29] while the latter plays a role in the pathogenesis of a variety of tumours [30].

Lastly we successfully detected the deletion of one allelic copy of the *OPA1* gene in an ADOA family. To date such genetic abnormalities can only be detected unequivocally by FISH. This requires live material and is therefore not always possible. This assay could be applied to any gene implicated in an autosomal dominant disease, in order to determine whether whole or partial gene deletion is a significant cause of disease. This SYBR green I assay could also be applied to a number of conditions where a tumour suppressor gene is involved in inherited susceptibility to cancer (p53, Rb, WT1, APC, VHL or BRCA1). In these conditions, one copy of the tumour suppressor gene is either mutated or deleted in the germ line, while the second copy is lost or mutated in the tumour itself. Genetic counselling could therefore benefit from a quick and reliable assay to determine carriers of such deletions.

## Methods

### **Peripheral Blood Mononuclear cell (PBMC) recovery from blood samples and DNA extraction**

PBMCs were recovered using a step gradient sucrose separation procedure (Lymphoprep, Ficomed, Oslo, Norway) from 5.0 ml of heparinized blood. DNA was extracted using a standard proteinase K (Roche, Mannheim, Germany) digestion (over night at 55 °C) followed by phenol/choloroform extraction (ready red, Appligen-Oncor, Ilkirch France) and DNA precipitation using ethanol. DNA was recovered by centrifugation, dissolved in TE

(TRIS 10 mM, EDTA 1 mM, pH8), and stored at -20°C. For the TREC assay, a further CD4+ T-cell separation was performed using magnetic depletion (CD4+ T-cell negative selection kit, Metachem, Meylan, France).

#### Real-time PCR

Real-time PCR was performed using an ABI 7700 Sequence Detection System (PE Applied-Biosystems) in the presence of SYBR-green. The optimisation of the real-time PCR reaction was performed according to the manufacturer's instructions (PE Applied-Biosystems, User Bulletin 2 applied to the SYBR-Green I core reagent protocol) but scaled down to 25 µl per reaction. The PCR conditions were standard (SYBR-Green I core reagent protocol) and all reagents were provided in the SYBR-Green I core reagent kit, including AmpliTaq-GOLD polymerase (PE Applied-Biosystems). After optimisation (see Results section), nucleotide primers were used at various concentrations for the detection and quantification of *GAPDH*, signal and coding TREC, *GLI*, *MYC-C*, *MYC-N*, *OPA1*, *FLAG* and Hop.

#### Determination of the levels of gene amplification using QM-Multiplex PCR

Gene dosage of *GLI* was analysed by Fluorescent Differential PCR employing FAM labelled oligonucleotide primers [18]. Two reference loci were also used: exon 19 of the cystic fibrosis transmembrane conductance regulator (*CFTR*) at 7q31 and ubiquitin-conjugating enzyme pseudogene (*UBE2L2*) at 12q12. PCR amplification was carried out in 30 µl 10 mM Tris-HCl buffer, pH 9.0, containing 50 mM KCl, 0.1% (v/v) Triton X-100, 1.5 mM MgCl<sub>2</sub>, 0.2 mM dNTPs, 5 µM of each primer for *UBE2L2* and *CFTR*, 100 ng of genomic DNA, 7.5 µM of the *GLI* primers and 2 units *Taq* DNA polymerase. PCR conditions consisted of an initial denaturation step of 95°C for 5 minutes, followed by 24 cycles of 95°C for 1 minute, 58°C for 1 minute and 72°C for 1 minute, with a final extension of 72°C for 10 minutes. A PCR using human genomic DNA as a control was routinely run in parallel. Moreover, experiments were performed in triplicate to ensure reproducibility of the technique. The FAM labelled products were separated through a denaturing polyacrylamide gel on an ABI 377 fragment analyser (PE Applied Biosystems). Quantitative analysis of the PCR products was performed using Genescan 672 software® (PE Applied Biosystems). *GLI* gene dosage was calculated by comparing the ratios of *GLI* to reference gene peak areas generated by control DNA with those generated by the cell line DNAs, as described [18]. Primer sequences were as follows: *GLI-F-d* TGA TGC AGT TCC TTT ATT ATC AGG; *GLI-R-(FAM)-d* AGA GTA GGG AAT CTC ATC CAT CA, giving a product of 200 bp. *UB-F(FAM)-d* CGA AGA GCA CAC TTA AAG ATC TG; *UB-R-d* GGT CAG CCT-GAA GTG GAT GCT CA generating a 173 bp product. *CFTR19-F-dCCT*

*ACC AAG TCA ACC AAA CC*; *CFTR19-R(FAM)-dACA TTG CTT CAG GCT ACT GG*; generating a product of 268 bp.

#### Author's contribution

FP, conceived the study, designed it, performed it and supervised the real time PCR work of other authors.

CT, performed the deletion work.

KB, performed the Fluorescent Differential PCR work.

FTL, performed the transgenic mouse work.

SHD, provided technical assistance to FP.

SMB, provided cell lines.

VC, provided neuroblastoma tumour samples

AP, provided neuroblastoma tumour samples

AJM, supervised the transgenic mouse project

PAR, supervised the Fluorescent Differential PCR work.

CFI, supervised the deletion work.

JDI, is head of group.

AFM, is head of department.

#### References

- de Kok JB, van Balken MR, Roelofs Rwhm, van Aarssen Yawg, Swinkels DW and Gunnewiek Jmtk: **Quantification of hTERT mRNA and telomerase activity in bladder washings of patients with recurrent urothelial cell carcinomas.** *Clin. Chem.* 2000, **46**:2003-2007.
- Homey B, Dieu-Nosjean MC, Wiesenborn A, Massacrier C, Pin JJ, Oldham E, Catron D, Buchanan ME, Muller A, Malefyt RD, Deng G, Orozco R, Ruzicka T, Lehmann P, Lebecque S, Caux C and Zlotnik A: **Up-regulation of macrophage inflammatory protein-3 alpha/CCL20 and CC chemokine receptor 6 in psoriasis.** *J. Immunol.* 2000, **164**:6621-6632.
- Kubo A, Nishitani V, Minamino N, Kikumoto K, Kurioka H, Nishino T, Iwano M, Shiiki H, Kangawa K and Dohi K: **Adrenomedullin gene transcription is decreased in peripheral blood mononuclear cells of patients with IgA nephropathy.** *Nephron* 2000, **85**:201-206.
- Holland PM, Abramson RD, Watson R and Gelfand DH: **Detection of Specific Polymerase Chain Reaction Product by Utilizing the 5' 3' Exonuclease Activity of Thermus aquaticus DNA Polymerase.** *PNAS* 1991, **88**:7276-7280.
- Takeshita S, Toda M and Yamagishi H: **Excision Products of the T-Cell Receptor Gene Support a Progressive Rearrangement Model of the Alpha-Delta Locus.** *Embo J.* 1989, **8**:3261-3270.
- Kinzler KW, Bigner SH, Bigner DD, Trent JM, Law ML, O'Brien SJ, Wong AJ and Vogelstein B: **Identification of an Amplified, Highly Expressed Gene in a Human Glioma.** *Science* 1987, **236**:70-73.
- Arheden K, Ronne M, Mandahl N, Heim S, Kinzler KW, Vogelstein B and Mitelman F: **In situ Hybridization Localizes the Human Putative Oncogene Gli to Chromosome Subbands 12q13.3-14.1.** *Hum. Genet.* 1989, **82**:1-2.

8. Fisher U, Meltzer P and Meese E: **Twelve amplified and expressed genes localised in a single domain in glioma.** *Hum Genet* 1996, **98**:625-628.
9. Khatib ZA, Matsushime H, Valentine M, Shapiro DN, Sherr CJ and Look AT: **Coamplification of the Cdk4 Gene with Mdm2 and Gli in Human Sarcomas.** *Cancer Res.* 1993, **53**:5535-5541.
10. De Preter K, Speleman F, Combaret V, Lunec J, Laureys G, Eusson BH, Francotte N, Pearson AD, De Paepe A, van Roy N and vander-sompele J: **Quantification of MYC-N, DDX1 and NAG gene copy number in neuroblastoma using real time quantitative PCR assay.** *Mod. Pathol.* 2002, **15**:150-166.
11. Toomes C, Murton NJ, Mackey DA, Craig JE, Newbury-Ecob RA, Bennett CP, Vize CJ, Desai SP, Black GCM, Patel N, Teimory M, Markham AF, Inglehearn CF, and Churchill AJ: **Spectrum, frequency and penetrance of OPA1 mutations in dominant optic atrophy.** *Human Molecular Genetics* 2001, **10**:1369-1378.
12. Marchbank NJ, Craig JE, Leek PJ, Toohey M, Churchill AJ, Markham AF, Mackey DA, Toomes C and Inglehearn CF: **Deletion in the OPA1 gene in a dominant optic atrophy family: evidence that haploinsufficiency is the cause of disease.** *J Med Genet* 2002, **39**:0-3.
13. Alexander C, Votruba M, Pesch UE, Thiselton DL, Mayer S, Moore A, Rodriguez M, LKellner U, Leo-Kottler B, Auburger G, Bhattacharya SS and Wissinger B: **OPA1, encoding a dynamin-dominant GTPase, is mutated in autosomal dominant optic atrophy linked to chromosome 3q28.** *Nature Genetics* 2000, **26**:211-215.
14. Douek DC, McFarland RD, Keiser PH, Gage EA, Massey JM, Haynes BF, Polis MA, Haase AT, Feinberg MB, Sullivan JL, Jamieson BD, Zack JA, Picker LJ and Koup RA: **Changes in thymic function with age and during the treatment of HIV infection.** *Nature* 1998, **396**:690-695.
15. Poulin JF, Viswanathan MN, Harris JM, Komanduri KV, Wieder E, Ringuette N, Jenkins M, McCune JM and Sekaly RP: **Direct evidence for thymic function in adult humans.** *J. Exp. Med.* 1999, **190**:479-486.
16. Ponchel F, Morgan AW, Bingham SJ, Quinn M, Buch M, Verburg RJ, Henwood A, Douglas SH, Masurel A, Conaghan P, Gesinde M, Taylor J, Markham AM, Emery P, van Laar JM and Isaacs JD: **Dysregulation lymphocyte proliferation and differentiation in patients with rheumatoid arthritis.** *Blood* 2002, **100**:4550-4556.
17. Robert WM, Douglas EC, Peiper SC, Houghton PJ and Look AT: **Amplification of the GLI gene in childhood sarcomas.** *Cancer Res* 1989, **49**:5497-5413.
18. An HX, Niederacher D, Beckmann MW, Gohring UJ, Scharl A, Picard F, Vanroeyen C, Schnurch HG and Bender HG: **ErbB2 Gene Amplification Detected by Fluorescent Differential Polymerase Chain-Reaction in Paraffin-Embedded Breast-Carcinoma Tissues.** *Int. J. Cancer* 1995, **64**:291-297.
19. Forgue-Lafitte ME, Coudray AM, Breant AH and Mester j.: **Proliferation of the human colon carcinoma cell line HT29: autocrine growth and deregulated expression of c-myc.** *Cancer Research.* 1989, **49**:6566-6571.
20. Hazenberg MD, Otto SA, Stuart Jwtc, Verschuren MCM, Borleffs JCC, Boucher CAB, Coutinho RA, Lange JMA, De Wit TFR, Tsegaye A, Van Dongen JJM, Hamann D, De Boer RJ and Miedema F: **Increased cell division but not thymic dysfunction rapidly affects the T-cell receptor excision circle content of the naive T cell population in HIV-1 infection.** *Nat. Med.* 2000, **6**:1036-1042.
21. Douek DC, Vescio RA, Betts MR, Brenchley JM, Hill BJ, Zhang L, Berenson JR, Collins RH and Koup RA: **Assessment of thymic output in adults after haematopoietic stem-cell transplantation and prediction of T-cell reconstitution.** *Lancet* 2000, **355**:1875-1881.
22. Koetz K, Bryl E, Spickschen K, O'Fallon WM, Goronzy JJ and Weyand CM: **T cell homeostasis in patients with rheumatoid arthritis.** *Proc. Natl. Acad. Sci. U. S. A.* 2000, **97**:9203-+.
23. Hazenberg MD, Borghans JAM, de Boer RJ and Miedema F: **Thymic output : a bad TREC record.** *Nature Immunology* 2003, **4**:97-99.
24. Ponchel F, Brown A, Douglas SH, Maltby S, Lawson C, Emery P and Isaacs JD: **Recovery of IL-7 expression normalises thymic activity and T-cell dysfunctions in rheumatoid arthritis patients in clinical remission.** *British Society of Rheumatology.* Edited by: 2003. *Manchester*; 2003.
25. Hazenberg MD, Otto SA, de Pauw ES, Roelofs H, Fibbe WE, Hamann D and Miedema F: **T-cell receptor excision circle and T-cell dynamics after allogeneic stem cell transplantation are related to clinical events.** *Blood* 2002, **99**:3449-3453.
26. Luthra R and Medeiros LJ: **5' -> 3' exonuclease-based real-time PCR methods for detecting the t(14;18) and t(11;14) in non-Hodgkin's lymphomas.** *J. Clin. Ligand Assay* 2000, **23**:6-14.
27. Estalilla OC, Medeiros LJ, Manning JT and Luthra R: **5' -> 3' exonuclease-based real-time PCR assays for detecting the t(14;18)(q32;21): A survey of 162 malignant lymphomas and reactive specimens.** *Mod. Pathol.* 2000, **13**:661-666.
28. Ramachandra C and Melnick SJ: **Multidrug resistance in human tumors : molecular diagnosis and clinical significance.** *Mol. Diag* 1999, **4**:81-94.
29. Vos CBJ, Ter Haar NT, Peterse JL, Cornelisse GJ and Van de Vijver MJ: **Cyclin D-1 gene amplification and overexpression are present in ductal carcinoma in situ of the breast.** *J. Pathol.* 1999, **187**:279-284.
30. Gunther T, Schneider-Stock R, Hackel C, Kasper HU, Pross M, Hackelsberger A, Lippert H and Roessner A: **Mdm2 gene amplification in gastric cancer correlation with expression of mdm2 protein and p53 alterations.** *Mod. Pathol.* 2000, **13**:621-626.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:  
http://www.biomedcentral.com/info/publishing\_adv.asp

